Supernus Pharmaceuticals | SUPN - Selling And Administration Expenses

Stock Price
48.51
Daily Change
0.35 0.73%
Monthly
-1.80%
Yearly
29.84%
Q1 Forecast
46.68

Supernus Pharmaceuticals reported $179.68M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Eisai JPY 103.86B 3.7B Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Novo Nordisk DKK 18.85B 2.74B Jun/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 3.19B 209M Sep/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
United Therapeutics USD 152M 60.5M Sep/2025
Xeris Pharmaceuticals USD 46.46M 2.07M Sep/2025